These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21659624)

  • 1. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I
    Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
    Mao ZL; Alak A; Wheeler JJ; Keirns J
    Drug Metab Lett; 2011 Apr; 5(2):114-25. PubMed ID: 21457140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
    Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
    Tian D; Frishman WH
    Cardiol Rev; 2011; 19(1):41-4. PubMed ID: 21135602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA; Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN; Eschenhagen T
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vernakalant for the conversion of atrial fibrillation of recent onset].
    Seoane L; Baranchuk A; Conde D
    Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.